Suppr超能文献

上海中年成年人低骨密度的高患病率:一项横断面研究。

High prevalence of low bone mineral density in middle-aged adults in Shanghai: a cross-sectional study.

作者信息

Chen Qian, Liu Dan, Li Xuefei, Li Fangfang, Guo Suxia, Wang Shiyun, Yuan Weina, Chen Pinghua, Li Pan, Li Fangyu, Zhao Changwei, Min Wen, Hu Zhijun

机构信息

Longhua Clinical Medical College of Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China.

Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China.

出版信息

BMC Musculoskelet Disord. 2024 Dec 30;25(1):1097. doi: 10.1186/s12891-024-08239-7.

Abstract

PURPOSE

To assess bone mineral density (BMD) in middle-aged individuals in Shanghai, in order to improve awareness of osteopenia and osteoporosis screening.

METHODS

The clinical data of 1107 permanent residents of Shanghai aged 40-60 years were collected using a random cluster sampling method. Osteoporosis questionnaire survey and BMD test were conducted. Mann-Whitney U and Chi-square test were used to compare sex, age and body mass index at different stages of bone mass, and Pearson test was used to conduct correlation analysis. Logistic regression was used to analyze the influencing factors.

RESULTS

The detection rates of osteopenia and osteoporosis were 59% and 12.5% respectively, and bone mineral density was correlated with sex, age, and body mass index (P < 0.05).

CONCLUSION

The incidence of low bone mass is high in the assessed population, screening for low bone mass should be actively carried out to improve public awareness. It is also good for public health management.

REGISTERED CLINICAL TRIAL

The trial was approved by Chinese Clinical Trial Registry on February 11, 2021(ChiCTR2100043369).

摘要

目的

评估上海中年人群的骨密度(BMD),以提高对骨质减少和骨质疏松症筛查的认识。

方法

采用随机整群抽样方法收集1107名40 - 60岁上海常住居民的临床资料。进行骨质疏松问卷调查和骨密度检测。采用曼-惠特尼U检验和卡方检验比较不同骨量阶段的性别、年龄和体重指数,采用Pearson检验进行相关性分析。采用逻辑回归分析影响因素。

结果

骨质减少和骨质疏松的检出率分别为59%和12.5%,骨密度与性别、年龄和体重指数相关(P < 0.05)。

结论

在评估人群中低骨量的发生率较高,应积极开展低骨量筛查以提高公众意识,这也有利于公共卫生管理。

注册临床试验

该试验于2021年2月11日获得中国临床试验注册中心批准(ChiCTR2100043369)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efa7/11687169/b41b24a37b75/12891_2024_8239_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验